DelveInsight projects 10% growth

1/ DelveInsight’s new forecast points to steady expansion in point-of-care molecular diagnostics through 2034, with demand centered on faster testing closer to patients rather than in centralized labs. (globenewswire.com) 2/ The core bet is decentralization: hospitals, clinics, pharmacies and other near-patient settings want molecular tests that can deliver actionable results without the turnaround times of traditional lab workflows. (globenewswire.com) 3/ That matters because molecular diagnostics used to be associated with specialized instruments, trained staff and tightly controlled lab environments. Moving those capabilities outward changes both the market opportunity and the engineering problem. (globenewswire.com) 4/ The growth story is not just about speed. It is also about portability, simpler operation and use cases where a delayed answer is less useful than a rapid one delivered at the point of care. (globenewswire.com) 5/ A related market report on mobile cancer-screening devices describes the same broader push: advanced diagnostics are being designed to travel closer to the patient, including in screening and early-detection settings. (openpr.com) 6/ In practice, that means companies are chasing systems with smaller footprints, fewer manual steps and workflows that can be used outside large reference laboratories. That is an inference from the reports’ emphasis on portability and near-patient deployment. (globenewswire.com) 7/ But portability raises the bar in another way. A test moved out of a central lab has to stay reliable when operators are less specialized, environments are less controlled and sample-handling conditions may vary more. (globenewswire.com) 8/ That is why the reports emphasize simpler workflows and stronger internal controls. A device that is easy to move but hard to run consistently does not solve much for clinicians or health systems. (globenewswire.com) 9/ The cancer-screening angle is notable because screening tools face a different challenge from acute diagnostic tools: they need to be practical enough for broader use while still producing dependable results in decentralized settings. (openpr.com) 10/ The commercial implication is straightforward. Vendors are not only competing on assay performance; they are also competing on usability, robustness and how well a platform holds up outside ideal laboratory conditions. That framing is supported by the reports’ focus on workflow simplicity and operation beyond central labs. (globenewswire.com) 11/ For buyers, the story is less “miniaturization for its own sake” than whether these systems can reduce friction in care delivery — faster answers, fewer handoffs and testing that fits where patients already are. This is an inference from the decentralization trend described in the reports. (globenewswire.com) 12/ The next thing to watch is whether future company filings, product launches and health-system rollouts back up the forecast with concrete adoption data, especially in near-patient molecular testing and mobile screening platforms. (globenewswire.com)